In addition to being asked, “Why CD24?” – I also get asked, “How is your lead drug candidate, PHST001, differentiated?” Due to the complex glycosylation patterns on CD24, not all antibodies against this target are created equal. We have engineered PHST001 to interact with all glyco-variants of CD24, which enables potent activity. And our preclinical data show that we are on the right track. Macrophage checkpoint inhibitors hold tremendous promise, and I believe that PHS001 can strike the right balance of safety and efficacy that is crucial to success. Thanks @PharmaShots for the opportunity to discuss the potential impact of PHST001, how it works, and the impact it could make on the field of cancer immunotherapy.
Our CEO and cofounder Roy Maute recently chatted with PharmaShots about how our lead candidate, PHST001 uniquely targets CD24 as a differentiated macrophage checkpoint inhibitor, what our preclinical data is telling us, and our plans for clinical trials. Read the Q&A here: https://lnkd.in/e9XjrmPF #immunotherapy #cancer #oncology #drugdevelopment #pharma #macrophages #macrophage #checkpointinhibitors #CD24
Your expertise and dedication are truly making a difference in the field of cancer immunotherapy. Keep up the fantastic work!
I know what some of those words mean 😅🙃
very cool
Protein Engineer and Structural Biologist Developing Antibody Therapies
2moGlycans are indeed important for antibody-antigen interactions and under appreciated